A Phase III Trial of Fluoropyrimidines (FP) Plus Bevacizumab (BEV) vs. Bev Alone, or No Treatment as Maintenance Strategy, Following a Standard Combination of FP, Oxaliplatin (OX), and Bev as First-Line Treatment for Patients with Metastatic Colorectal Cancer (MCRC): AIO KRK 0207
Titel:
A Phase III Trial of Fluoropyrimidines (FP) Plus Bevacizumab (BEV) vs. Bev Alone, or No Treatment as Maintenance Strategy, Following a Standard Combination of FP, Oxaliplatin (OX), and Bev as First-Line Treatment for Patients with Metastatic Colorectal Cancer (MCRC): AIO KRK 0207
Auteur:
Arnold, D. Lerchenmüller, C. Killing, B. Depenbusch, R. Steffens, C.C. Al-Batran, S.E. Quidde, J. Lange, T. Dietrich, G. Stoehlmacher, J. Reinacher-Schick, A. Tannapfel, A. Graeven, T. Schmoll, H.J. Hegewisch-Becker, S.